Abstracts tagged "Biologicals"

Abstract Number: 0361 • ACR Convergence 2023
Safety of Golimumab Dose Escalation in Pediatric Autoimmunity: A Single Institution Retrospective Experience
Leah Medrano and Alice Hoftman, David Geffen School of Medicine, UCLA, Los Angeles, CA
Background/Purpose: There is limited data on pediatric golimumab dose escalation, with some data available only in the adult literature. The subcutaneous formulation is not approved…
Abstract Number: 0458 • ACR Convergence 2023
Drug Switching Due to Inefficacy in Rheumatoid Arthritis Patients Treated with Biological and Targeted Therapies. Daily Clinical Experience
Maria Rodriguez Laguna¹, Zulema Rosales-Rosado², Cristina Vadillo-Font¹, Jose Pierre Otazu-Moudelle¹, Inés Pérez Sancristóbal¹ and lydia Abasolo², ¹Hospital Clinico San Carlos, Madrid, Spain, ²Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: The treatment of Rheumatoid Arthritis (RA) has undergone an enormous change in the last two decades with the use of biological Disease Modifying Drugs…
Abstract Number: 0592 • ACR Convergence 2023
Real-World Treatment Patterns in Patients with Systemic Lupus Erythematosus: An Analysis of the SLE Prospective Observational Cohort Study (SPOCS)
Martin Aringer¹, Laurent Arnaud², Richard A. Furie³, Eric Morand⁴, Christine Peschken⁵, Barnabas Desta⁶, Eleni Rapsomaniki⁷, Jonatan Hedberg⁸, Tina Grünfeld Eén⁸, Alessandro Sorrentino⁹, Canna Ghia⁹, Stephanie Chen¹⁰ and Bo Ding⁸, ¹Faculty of Medicine TU Dresden, Dresden, Germany, ²University Hospitals of Strasbourg, Strasbourg, France, ³Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ⁴Monash University, Centre for Inflammatory Diseases, Melbourne, Australia, ⁵University of Manitoba, Winnipeg, MB, Canada, ⁶BioPharmaceuticals R&D, AstraZeneca, Gaithersburg, MD, ⁷BioPharmaceuticals Medical, AstraZeneca, Cambridge, United Kingdom, ⁸BioPharmaceuticals Medical, AstraZeneca, Gothenburg, Sweden, ⁹Medical Affairs, AstraZeneca, Cambridge, United Kingdom, ¹⁰BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, MD
Background/Purpose: The international SLE Prospective Observational Cohort Study (SPOCS) collected data on patients with moderate to severe SLE disease activity from June 2017 through November…
Abstract Number: 0971 • ACR Convergence 2023
Network Meta Analyses of the Effectiveness and Safety Profiles of Janus Kinase Inhibitors and Biologic Agents in Treating Children with Non-systemic Juvenile Idiopathic Arthritis (nsJIA)
Bin Huang¹, Yuxiang Li², Xiaomeng Yue³, Sandra Andorf², Daniel J Lovell⁴ and Hermine Brunner⁵, ¹Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ²Cincinnati Children's Hospital Medical Center, Cincinnati, OH, ³James L. Winkle College Pharmacy, Cincinnati, OH, ⁴UC Department of Pediatrics, Cincinnati Children's Hospital, University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: Tofacitinib (TOFA, NCT02592434) and Baricitinib (BARI, NCT03773978) are Janus kinase inhibitors (JAKi) that are approved for or being tested for nsJIA treatment. We aim…
Abstract Number: 1167 • ACR Convergence 2023
Transcriptome Analysis of Peripheral Blood Reveals Superiority of the Triple Combination of Baricitinib, Rituximab, and Tacrolimus Therapy (BRT-Tx.) for anti-MDA5 Antibody-positive Dermatomyositis (MDA5-DM)
Yoshinobu Koyama¹, Yoshiharu Sato², Yu Nakai³ and Moe Tokunaga(Sakamoto)³, ¹Japanese Red Cross Okayama Hospital, Okayama, Japan, ²DNA Chip Research Inc, Tokyo, Japan, ³Rheumatology, Center for Autoimmune diseases, Japanese Red Cross Okayama Hospital, Okayama, Japan
Background/Purpose: MDA5-DM is characterized by high mortality due to rapid progressive ILD. We reported that in MDA-5DM, (1) RIG-1-like receptor signaling is enhanced, (2) antiviral…
Abstract Number: 1379 • ACR Convergence 2023
Population Pharmacokinetic/Pharmacodynamic Modeling of Dazodalibep, a CD40L Antagonist, in Healthy Volunteers and Patients with Rheumatoid Arthritis and Sjogren’s Syndrome
Kenneth Der¹, Ryan Crass², Brendan Smith³, Wonkyung Byon⁴, Yan Xin⁵ and Jiayin Huang⁶, ¹Horizon Therapeutics, Danville, CA, ²Apellis Pharmaceuticals, Michigan, ³A2-Ai, Michigan, ⁴Amador Bioscience, Michigan, ⁵Horizon Therapeutics, South San Francisco, CA, ⁶Horizon Therapeutics, Chicago, IL
Background/Purpose: Sjögren's (SjS) is a chronic, systemic autoimmune disease caused by aberrant activation and infiltration of lymphocytes. Dazodalibep (DAZ), a novel non-antibody biologic antagonist of…
Abstract Number: 1504 • ACR Convergence 2023
Characteristics and Prior Treatment Journey of Systemic Lupus Erythematosus (SLE) Patients Who Were Prescribed Anifrolumab — Observations from the American Rheumatology Network (ARN) in the U.S
Vasileios Kyttaris¹, Gelareh Atefi², Daniel Persons³, Christopher S. Ambrose⁴, Scott Milligan⁵ and Sandra Wu⁶, ¹BIDMC, Boston, MA, ²BioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, ³Trio Health, Denver, CO, ⁴AstraZeneca, Wilmington, DE, ⁵Trio Health, Analytics, Louisville, CO, ⁶AstraZeneca, Hockessin, DE
Background/Purpose: FDA-approved for moderate-severe SLE in August 2021, anifrolumab is a type I interferon (IFN) receptor antagonist that has been shown to decrease lupus flares…
Abstract Number: 1962 • ACR Convergence 2023
Toll-Like Receptor 7/8 Activation of Immune and Non-Immune Cells in Muscle by RNA-Containing Immune Complexes Can Contribute to Inflammation and the Pathogenesis of Myositis
Yin Wu¹, Aditee Deshpande¹, Nicholas Geraci¹, Vera Sellers², Phanindra Velisetty², David Fiorentino³, Kavita Y. Sarin³ and Andrew Bender¹, ¹Research Unit – Neurology and Immunology, EMD Serono, Billerica, MA, ²Discovery Technologies, EMD Serono, Billerica, MA, ³Department of Dermatology, Stanford University, Redwood City, CA
Background/Purpose: Tissue inflammation is a major disease driver in idiopathic inflammatory myopathies (IIM), leading to muscle weakness and, in the case of dermatomyositis (DM), a…
Abstract Number: 2193 • ACR Convergence 2023
Anti-citrullinated Protein Antibodies in Sjögren’s Syndrome Define a Subset of Patients with Lower B Cell Activation Markers and Higher Risk of Lung Involvement
Augusto Silva¹, Filipa Costa², Mariana Silva², Giovanni Fulvio³, Matilde Bandeira², Manuel Silvério-António⁴, Nikita Khmelinskii², Chiara Baldini³ and Vasco Romão², ¹Santa Maria Hospital, Maceira, Portugal, ²Centro Hospitalar Universitário Lisboa Norte, Lisboa, Portugal, ³University of Pisa, Pisa, Italy, ⁴Hospital Santa Maria, Lisboa, Portugal
Background/Purpose: Extraglandular manifestations may occur in up to 40-50% of patients with SS, including inflammatory arthralgia and chronic polyarthritis (1-3). ACPA are prototypical markers of…
Abstract Number: 2251 • ACR Convergence 2023
Direct and Indirect Effects of Upadacitinib or Adalimumab on Pain in Psoriatic Arthritis: Results from a Randomized Phase 3 Study
Peter C. Taylor¹, David Walsh², Tsutomu Takeuchi³, Bruno Fautrel⁴, Janet Pope⁵, Koji Kato⁶, Arathi Setty⁶, Tianming Gao⁶, Diane Caballero⁷, Ralph Lippe⁸ and Arthur Kavanaugh⁹, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Nottingham, Nottingham, United Kingdom, ³Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁴Sorbonne Université APHP, Paris, France, ⁵University of Western Ontario, London, ON, Canada, ⁶AbbVie, Inc., North Chicago, IL, ⁷AbbVie, Inc., Chicago, IL, ⁸AbbVie Deutschland GmbH & Co. KG, Wiesbaden, Germany, ⁹University of California San Diego, School of Medicine, Riverside, CA
Background/Purpose: Pain, including inflammatory joint pain, may be debilitating in patients with psoriatic arthritis (PsA). Pain in PsA is multidimensional and can be influenced via…
Abstract Number: 2537 • ACR Convergence 2023
Implementation of a Best Practice Advisory to Improve Infection Screening Prior to New Prescriptions of Biologics and Targeted Synthetic Drugs
Hailey Baker¹, Rebecca Fine¹, Fenn Suter², Heather Allore³, Betty Hsiao⁴, Vaidehi Chowdhary⁵, Elizabeth Lavelle⁶, Ping Chen⁶, Richard Hintz⁶, Lisa Suter⁷ and Abhijeet Danve⁸, ¹Yale New Haven Hospital, New Haven, CT, ²Georgetown University, Washington, DC, ³Yale University, Yale School of Medicine, New Haven, CT, ⁴Yale-New Haven Medical Center, New Haven, CT, ⁵Yale University, New Haven, CT, ⁶Yale New Haven Health, New Haven, CT, ⁷Yale School of Medicine, New Haven, CT, ⁸Yale University School of Medicine, Glastonbury, CT
Background/Purpose: Biologic and targeted synthetic DMARDs (b/tsDMARDs) are widely used to treat patients with various autoimmune inflammatory diseases (ARD). Use of a b/tsDMARD in patients…
Abstract Number: 0376 • ACR Convergence 2023
Switching Patterns of Biological and Targeted Synthetic Therapies in Juvenile Idiopathic Arthritis
Daniel clemente Garulo¹, Alina Lucica Boteanu², Laura Trives Folguera³, Antía Asunción García Fernández², lydia Abasolo⁴, Leticia Leon⁵, Juan Carlos López Robledillo⁶ and Juan carlos Nieto-Gonzalez⁷, ¹Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, ²Hospital Universitario Ramon y Cajal, Madrid, Spain, ³Hospital Universitario Infanta Sofía, Madrid, Spain, ⁴Hospital Clínico San Carlos, Madrid, Spain, ⁵Fundación Investigación Biomédica Hospital Clínico San Carlos, Madrid, Spain, ⁶Hospital Universitario Niño Jesus, Madrid, Spain, ⁷Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: New therapies have improved the therapeutic management of juvenile idiopathic arthritis (JIA), allowing disease control in cases that are refractory or intolerant to methotrexate.…
Abstract Number: 0477 • ACR Convergence 2023
Continuing TNFi After Pregnancy Diagnosis in Women with Chronic Rheumatic Inflammatory Diseases Is Not Associated with Worse Obstetrical or Infant Outcomes and Seems to Reduce Risk of Maternal Severe Infection: The Results of the Emulated Target Trial BioGRIC
Anna Molto¹, aya ajrouche², Diep Tran², Nathalie Costedoat-Chalumeau³, Elisabeth Elefant⁴, Vassilis Tsatsaris⁵, Jeanne Fresson⁶, Brigitte Bader-Meunier⁵, Bruno Fautrel⁷ and Florence Tubach², ¹HOPITAL COCHIN AP-HP, Service de Rhumatologie, Paris, France, ²Centre de pharmaco-épidémiologie de l'APHP, Paris, France, ³Inserm DR Paris 5, Paris, France, ⁴APHP, Paris, France, ⁵Paris-Cité University, Paris, France, ⁶CHU Nancy, Nancy, France, ⁷Sorbonne Université APHP, Paris, France
Background/Purpose: Many women with chronic rheumatic inflammatory diseases (CRID) stop tumor necrosis factor inhibitors (TNFi) treatment once pregnancy is confirmed to avoid potential adverse fetal…
Abstract Number: 0594 • ACR Convergence 2023
Baseline Innate Immunity Transcriptional Signatures Act as Predictors of Response to Immunosuppressive and Biologic Treatments in Systemic Lupus Erythematosus While Disturbances Linked to p53-signaling Define “Resistant” Disease
Panagiotis garantziotis¹, Georgia-Savina Moysidou², stavros doumas³, Dionysis nikolopoulos², Sofia Flouda⁴, Noemin kapsala², Anastasia Filia², George Sentis², Antonis Fanouriakis², George Bertsias⁵ and Boumpas Dimitrios⁶, ¹Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, ²School of Medicine, National and Kapodistrian University of Athens, Athens, Greece, ³Department of Medicine, MedStar Georgetown University Hospital, Washington, DC, ⁴Unit of Attikon University Hospital, Athens, Greece, ⁵Rheumatology, Clinical Immunology and Allergy Department, Medical School, University of Crete, Greece; Institute of Molecular Biology and Biotechnology, Foundation for Research and Technology Hellas (FORTH), Heraklion, Greece, ⁶National and Kapodistrian University of Athens, Athens, Greece
Background/Purpose: Despite recent advances, the current state of SLE therapeutics remains largely empirical with existing immunosuppressive treatments failing to induce remission in over 40% of…
Abstract Number: 0979 • ACR Convergence 2023
Use and Discontinuation of Tumour Necrosis Factor Inhibitors Among Pregnant Women with Chronic Inflammatory Diseases
Leah K. Flatman¹, Sasha Bernatsky², Isabelle Malhamé³, Yvan St. Pierre², Olga Basso¹, Anick Bérard⁴ and Evelyne Vinet⁵, ¹McGill University, Montreal, QC, Canada, ²Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ³McGill University Health Centre, Montreal, QC, Canada, ⁴University of Montreal, Montreal, QC, Canada, ⁵McGill University Health Centre, Montréal, QC, Canada
Background/Purpose: Early consensus statements recommended discontinuing tumour necrosis factor inhibitors (TNFi) during pregnancy. Despite new guidelines recommending against this, the choice to stop TNFi pre-conception…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].